Halbert Hargrove Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2	Closed	-$964	–	690
2026 Q2	$964	Buy	+2	New	+$886	﹤0.01%	447
2025 Q4	–	Sell	-13	Closed	-$5.09K	–	736
2025 Q3	$5.09K	Buy	+13	New	+$5.43K	﹤0.01%	415
2025 Q2	–	Sell	-5	Closed	-$2.26K	–	651
2025 Q1	$2.26K	Buy	+5	New	+$2.33K	﹤0.01%	394

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Halbert Hargrove Global Advisors's VRTX Position: Q3 2026 in Review

Halbert Hargrove Global Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 2 shares — an estimated $964 sold.

Halbert Hargrove Global Advisors first reported a position in VRTX in Q1 2025 and held it in 3 quarters. The position peaked at $5.09K in Q3 2025. 700 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Halbert Hargrove Global Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Halbert Hargrove Global Advisors sold 2 Vertex Pharmaceuticals shares in Q3 2026, an estimated $964.
Halbert Hargrove Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Halbert Hargrove Global Advisors's Vertex Pharmaceuticals position peaked at $5.09K in Q3 2025.
700 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.